Neuroone Medical Technologies (NMTC) Q2 2025 Earnings Call May 13, 2025 08:30 AM ET Speaker0 Good day, ladies and gentlemen. Welcome to the Second Quarter of fiscal year two thousand twenty five financial results conference call for NeuroOne Medical Technologies Corporation. Today's call will be conducted by the company's chief executive officer, Dave Rosa, and Ron McClurg, the company's Chief Financial Officer. Chris Volker, the company's Chief Operating Officer, will also be in attendance. Before I turn t ...

Exhibit 99.1 NeuroOne Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6% Filed 510(k)Submission with FDA for OneRF Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicat ...

Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 Commission File Number ...

Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial result ...

Core Viewpoint - NeuroOne Medical Technologies Corporation is set to release its financial results for the fiscal second quarter ending March 31, 2025, on May 13, 2025, before market open [1] Group 1: Financial Results Announcement - The financial results will be discussed in an investor conference call and webcast scheduled for May 13, 2025, at 8:30 a.m. Eastern time [2] - Participants can join the call using specific dial-in numbers and access codes provided [2] Group 2: Company Overview - NeuroOne is focused on developing minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation for patients with neurological disorders [4] - The company aims to improve patient outcomes and reduce procedural costs, with potential applications in various areas including depression, mood disorders, and high blood pressure [4]

Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. Dear Shareholders, In recent months, NeuroOne has achieved sever ...

Core Insights - NeuroOne Medical Technologies Corporation has developed the OneRF® Ablation System, which has successfully treated a pediatric epilepsy patient, Clara Fuller, who previously experienced up to 10 seizures per night, resulting in her being completely seizure-free post-treatment [1][2][3] Company Overview - NeuroOne is focused on improving surgical care options for patients with neurological disorders, including epilepsy, Parkinson's disease, and chronic pain, through minimally invasive and high-definition solutions [4] - The company is exploring additional applications for its technology in areas such as depression, mood disorders, and pain management [4] Technology Impact - The OneRF® technology allows for minimally invasive radiofrequency ablation of seizure-causing brain tissue, significantly improving the quality of life for patients like Clara [2][3] - The successful treatment of Clara Fuller highlights the potential of the OneRF® platform to advance care for patients with debilitating neurological conditions [3]

Core Viewpoint - NeuroOne Medical Technologies Corporation has announced a public offering of 16,000,000 shares of common stock at a price of $0.50 per share, aiming to raise approximately $8,000,000 in gross proceeds for general working capital purposes [1][3]. Group 1: Offering Details - The offering consists entirely of shares sold by the Company, with an additional 45-day option for the underwriter to purchase up to 2,400,000 additional shares at the public offering price [2]. - The expected gross proceeds from the offering, before deductions, are $8,000,000, with the closing anticipated on or about April 7, 2025, subject to customary conditions [3]. Group 2: Regulatory Information - The shares will be issued under a shelf registration statement on Form S-3, which was declared effective by the SEC on August 16, 2024 [4]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [4]. Group 3: Contact Information - For further inquiries, contact information for the MZ Group is provided, including a phone number and email address [7][8].

Company Overview - NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients with neurological disorders [1][2]. Proposed Offering - The company has commenced a proposed underwritten registered public offering of shares of its common stock, with all shares to be sold by the company [1][2]. - The company intends to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares sold in the offering [2]. - The offering is subject to market and other conditions, with no assurance on the completion, size, or terms of the offering [2]. Underwriter Information - Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the proposed offering [3]. Regulatory Compliance - The proposed offering is made pursuant to a shelf registration statement on Form S-3, which was declared effective by the U.S. Securities and Exchange Commission on August 16, 2024 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the SEC's website [4].

Core Insights - NeuroOne Medical Technologies Corporation is focused on improving surgical care for patients with neurological disorders, particularly epilepsy, through innovative technology [1][5] - The OneRF® Ablation System is a significant advancement in epilepsy treatment, being the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [3][4] Company Overview - NeuroOne is developing minimally invasive solutions for EEG recording, brain stimulation, and ablation for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5] - The company aims to enhance patient outcomes and reduce procedural costs while exploring applications in other areas such as depression and high blood pressure [5] Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing medication-resistant seizures, highlighting the need for alternative treatment options like RF ablation therapy [2] - The OneRF® system offers a more efficient and precise approach for patients who do not respond to traditional medication, potentially reducing the need for multiple invasive surgeries [4]